Single Batch Release vs. Full Validation
Choosing the Right Sterilization Strategy for Your Product Lifecycle
Sterilization goes beyond a regulatory requirement, serving as a critical component of your product’s overall development and commercialization strategy. As medical device companies navigate early feasibility, clinical builds, and full-scale manufacturing, the question often arises: should you pursue single batch release or full validation?
A recent article by Medical Product Outsourcing offers a helpful overview of these approaches. However, it simplifies several important aspects of how single batch release actually works under ISO 11135, particularly Annex E. Understanding these nuances is essential for making the right decision.
What Is Single Batch Release?
Single batch release is a narrowly defined validation outline in Annex E of ISO 11135, designed for situations where only enough product exists to process a single sterilization load, rather than a shortcut to validation.
This approach is typically used during early-stage development, such as feasibility studies or limited clinical builds, where generating large quantities of product is not yet practical.
A key point that is often misunderstood: single batch release is not meant to be used repeatedly for routine market release. Annex E makes it clear that this method should not replace a full validation unless it is incorporated into a broader validation strategy.
How the Process Actually Works
Some descriptions of single batch release oversimplify the process, portraying it as two independent cycles with fixed testing quantities. In reality, Annex E outlines a more structured approach:
- A half-cycle exposure is performed first
- The same load then undergoes a full-cycle exposure
- Aeration is required between exposures
- Testing is conducted after each phase
The emphasis is not on arbitrary unit counts, but on demonstrating that the process achieves the required sterility assurance level under defined conditions.
Importantly, the same product load is used throughout the process. Any explanation that treats these as separate batches or assumes fixed sample numbers does not accurately reflect the standard.
Where Oversimplification Becomes Risky
In practice, ISO 11135 requires a much broader evaluation.
Beyond sterility testing, manufacturers must also consider:
- Residuals testing to ensure safe levels of sterilant byproducts
- Packaging integrity to confirm sterile barrier performance
- Physical parameter equivalence to document that process conditions are consistent and controlled
- Comprehensive documentation supporting the release decision
Full Validation: The Long-Term Standard
Full validation remains the gold standard for products moving toward commercialization. It establishes a reproducible, scalable sterilization process that supports routine manufacturing and regulatory approval.
While it requires more upfront investment in time and product, full validation provides:
- Confidence in process consistency
- Alignment with regulatory expectations
- A clear path to ongoing production
For products intended for market release, full validation is not just preferred, it is expected.
Aligning Strategy with Product Lifecycle
The most important takeaway is this: a sterilization strategy should align with where your product is going.
Single batch release can be appropriate when:
- Product availability is extremely limited
- You are in early feasibility or clinical stages
- You need initial data to support development
Full validation becomes essential when:
- You are preparing for commercialization
- Manufacturing will be repeated and scaled
- Regulatory submissions require validated processes
When sterilization is treated as part of the overall product strategy, rather than a box to check, the right path becomes much clearer.
The Bottom Line
Single batch release and full validation are not interchangeable options. They serve different purposes within the product lifecycle and are governed by different expectations under ISO 11135.
Choosing the right approach requires more than comparing cost or sample sizes. It requires a clear understanding of regulatory requirements, product maturity, and long-term manufacturing plans.
At Canyon Labs, we help partners navigate these decisions with a focus on both compliance and strategy, ensuring that your sterilization approach supports not just where you are today, but where you are headed next.